Obstructive jaundice is a common manifestation of malignancies involving pancreaticobiliary area of the gastrointestinal tract. The palliation of obstructive jaundice involves bypassing the obstruction by an endoprosthesis using either endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic biliary drainage route. Endoscopic ultrasound-guided choledochoduodenostomy (ECD) is a challenging alternative for obstructive jaundice due to distal bile duct obstruction in patients who have failed ERCP. In this report, we describe a challenging case of disseminated urinary bladder cancer that presented with extensive duodenal as well as periduodenal infiltration leading on to gastrointestinal bleed and severe pruritus along with obstructive jaundice and was successfully managed with initial argon plasma coagulation of bleeding duodenal lesions followed by ECD.
duodenoscope for completion of the procedure through the transpapillary route. (ii) Direct transmural stenting using transgastric hepaticogastrostomy or transduodenal choledochoduodenostomy [ECD] without accessing the papilla. (iii) Antegrade transpapillary stent placement following intrahepatic bile duct puncture. [1] [2] [3] [4] [5] [6] [7] The advantage of EUS-BD over percutaneous BD is that it maintains internal BD. However, in contrast to ERCP and PTBD, it is associated with high complication rates of up to 26% with bile leak being an important complication. [7] Furthermore, in the presence of extensively infiltrated duodenal mucosa, its safety is not well established.
Here, we describe a challenging case of disseminated urinary bladder cancer that presented with extensive duodenal as well as periduodenal infiltration leading on
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IntroductIon E xtrahepatic biliary obstruction is one of the common manifestations of malignancies involving pancreatic biliary area of gastrointestinal tract, and it usually requires palliation. The obstruction can be bypassed either by placing an endoprosthesis through the papilla using endoscopic retrograde cholangiopancreatography (ERCP) or percutaneously using image-guided transhepatic route. ERCP is successful in more than 90% of patients who have normal upper gastrointestinal tract anatomy with no luminal obstruction. However, in cases where ERCP is not possible due to various factors such as failed cannulation, obstructed/altered upper gastrointestinal tract anatomy, distorted ampulla, and large periampullary diverticulum, endoscopic ultrasound-guided biliary drainage (EUS-BD) is being increasingly performed as an alternative to percutaneous transhepatic BD (PTBD). [1] [2] [3] [4] [5] [6] [7] There are three ways of performing EUS-BD: (i) rendezvous technique, in which guidewire is passed through the papilla through a punctured intrahepatic or extrahepatic bile duct and retrieved by to gastrointestinal bleed and severe pruritus along with obstructive jaundice and was successfully managed with initial argon plasma coagulation (APC) of bleeding duodenal lesions followed by ECD.
cAse report
A 58-year-old male, known case of transitional cell carcinoma of urinary bladder, presented elsewhere with jaundice, pruritus, and melena. The patient was diagnosed as transitional cell carcinoma of urinary bladder 32 months ago when he was evaluated for hematuria. The patient underwent radical cystectomy and was apparently asymptomatic till 4 weeks ago when he developed gradually progressive obstructive jaundice associated with severe pruritus that was refractory to medical therapy. It was followed by melena 2 weeks later and gradually jaundice also deepened. Investigations revealed anemia (hemoglobin of 5.2 g/dl) and conjugated hyperbilirubinemia (total of 18 mg% with conjugated being 12.6 mg%). Upper gastrointestinal endoscopy revealed narrowing at junction of first and second part of duodenum with extensive infiltration and oozing of fresh blood from the site of narrowing. The gastroscope could not be negotiated beyond the narrowing. Contrast-enhanced computed tomography revealed dilated biliary radicals and common bile duct (CBD) with large lymph nodal mass obstructing the lower part of bile duct [ Figure 1a and b]. Ultrasound-guided fine-needle aspiration from the lymph nodal mass revealed it to be metastasis from bladder cancer. Patient was given multiple blood transfusions and referred to our center.
A repeat gastroscopy was performed, and it revealed infiltrated mucosa in both first of duodenum as well as narrowed junction of first and second part of duodenum from where fresh blood was oozing. APC of the bleeding duodenal lesions was done. Following this, the bleeding stopped and the patient was subsequently taken up for ECD after taking informed consent. EUS was done using a linear echoendoscope (GF-UCT 180, Olympus Medical Systems Co., Tokyo, Japan) along with carbon dioxide insufflation and it revealed a dilated CBD that was obstructed at the lower end with a large lymph nodal mass [ Figure 2 ]. The duodenal wall at the site of narrowing was also thickened with loss of wall stratification [ Figure 2 ]. The CBD was punctured from the first part of duodenum, avoiding the infiltrated, thickened duodenal wall using a 19G Flexible EUS needle (Expect, Boston Scientific, Natick, Massachusetts) [ Figure 3a and b]. The cholangiogram revealed a dilated CBD with cutoff at the lower end [ Figure 4 ]. Thereafter, a guidewire (VisiGlide; 0.025 inch; straight tip; Olympus Medical Systems Co., Tokyo, Japan) was advanced to the hilar side of the CBD [ Figure 5 ]. A fully covered self-expanding metallic stent (SEMS) (WallFlex; 10 mm diameter, 6 cm length, Boston Scientific, Natick, Massachusetts) was placed into the bile duct after dilatation of the transmural tract over the guidewire [ Figure 6 ]. The patient had an uneventful postprocedure course, and the pruritus subsided within 3 days of the procedure and jaundice started decreasing. The patient was thereafter referred to oncology services for further management.
On follow-up, patient became anicteric 14 days after the procedure and is jaundice free after 2 months of follow-up. There has also been no recurrence of gastrointestinal bleed. [8] first reported new technique of EUS-guided bilioduodenal anastomosis, there has been a gradual improvement in technique as well as accessories, and now EUS-BD is being increasingly performed in cases where ERCP is not possible. [1] [2] [3] [4] [5] [6] [7] A systematic review of 42 studies with 1192 patients reported that the technical success rate and functional success rate of EUS BD are high (94.71% and 91.66%, respectively). [9] However, it is also associated with high adverse events with frequency as high as 23.32%. This increased frequency of adverse events, namely, bleeding, bile leakage, pneumoperitoneum, stent migration, cholangitis, and peritonitis limits its widespread use.
Of the various options available for EUS BD, studies have shown varying results with majority showing that both rendezvous as well as direct transluminal stenting techniques as well as both transhepatic route and transduodenal route are equally safe and effective and therefore the choice of route of access and technique used usually depends on the endoscopist's preference. [9] [10] [11] [12] [13] The most concerning complication of transluminal EUS-BD is bile leakage and bleeding. Bile leakage can be theoretically prevented by the use of FCSEMS that can seal the gap between the stent and the walls of the fistula by expansion. [6] Our case was more challenging as there was an increased risk of bleeding because of extensive bleeding duodenal infiltration. We initially used APC to coagulate the bleeding lesions and thereafter carefully chose the transmural site of puncture avoiding the involved duodenal area and finally used fully covered SEMS that would have enhanced hemostasis by tamponade effect. conclusIon EUS-guided choledochoduodenostomy using a fully covered SEMS is a safe and effective treatment option for relieving malignant biliary obstruction even in the presence of extensive bleeding duodenal infiltration that has been initially controlled by APC.
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